Basal Insulin in Vulnerable Patients with Type 2 Diabetes WebCAST
The Physiologic Rationale for Optimizing HA1c Target Goal Attainment with Basal Insulin:
Mechanisms, Patient Selection and Sequencing Strategies— Why Long-Acting Insulin Matters as a Foundational Approach for the Diabetes and Endocrine Specialist: Addressing Challenges in Complex and Vulnerable Patients with T2D
Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in Challenging Patients with T2D
Why, When, and in Whom Do ADA/EASD Guidelines Recommend “Physiologic” Basal Insulin for T2D? The Evidence for the Safety and Efficacy of Long-Acting Insulin
Applying Updated ADA/EASD Guidelines to an Early-Onset Patient with T2D The Patient Who Has Not Achieved Ideal HA1c Levels after Metformin Alone and/or Metformin plus an SGLT-2 Inhibitor
Optimizing Glycemic Control in the Older or Elderly Patient with T2D at Risk for Hypoglycemia
What is the Mechanistic Rationale for Early Initiation of a Physiologic, Basal Insulin in Vulnerable Patients Who Require Intensified Glycemic Control?
In Whom, When and How? Optimizing Safety and Regimen Adherence with Improved Devices, Formulations, Dosing Vigilance and Delivery Systems for Long-Acting Insulin
Presentations, interactive discussion, and evaluation of two patients who have been on various insulin formulations who present with specific clinical profiles, safety needs, and glycemic dysregulation issues.
Focus on Using Long-Acting Insulin in Combination with Oral and Other Agents to Improve Health and Disease Metrics of Patients with Diabetes
38-year-old male with T1D since age 14. He has mild hyperlipidemia, celiac disease and no other significant medical problems. He runs regularly and struggles with eating the “right diet”. He reports occasional feelings of “impending low sugar” at night
